Maureen Mayes, MD
Rheumatology · Houston, TXNPI 1255364238
Payments from drug & device makers
Across 327 payments — averaging $4814.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$674K
- Boehringer Ingelheim$331K
- Seagen Inc.$137K
- AstraZeneca$131K
- Bristol Myers Squibb$58K
- Tanabe Pharma America, Inc.$46K
- plus $197K from 16 others
Across 8 payments — averaging $116.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$930
What the payments were for
- Consulting fees$49,43459%
- Speaking & faculty fees$23,02927%
- Travel & lodging$7,7139%
- Food & beverage$3,5804%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 14 | $673,861 |
| Boehringer Ingelheim | 22 | $330,677 |
| Seagen Inc. | 2 | $137,472 |
| AstraZeneca | 6 | $130,846 |
| Bristol Myers Squibb | 2 | $58,389 |
| Tanabe Pharma America, Inc. | 26 | $45,820 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 3 | $45,004 |
| Boehringer Ingelheim International GmbH | 96 | $36,156 |
| GSK | 6 | $22,976 |
| CSL Behring | 13 | $19,863 |
| Merck | 26 | $16,843 |
| Astrazeneca UK Limited | 11 | $14,622 |
| E.r. Squibb & Sons, L.L.C. | 4 | $11,507 |
| Sanofi US Services Inc. | 2 | $10,093 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 67 | $9,637 |
| Argenx US, Inc. | 2 | $5,400 |
| Novartis | 14 | $2,524 |
| Actelion Pharmaceuticals US, Inc. | 1 | $1,550 |
| Kadmon Corporation LLC | 1 | $644 |
| AbbVie | 4 | $351 |
| UCB, Inc. | 2 | $188 |
| Johnson & Johnson | 3 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,574,459 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XeljanzTofacitinib Citrate | 12 | $68,905 |
| Mycophenolate Mofetil | 57 | $18,506 |
| Sildenafil Citrate | 22 | $8,367 |
| Hydroxychloroquine Sulfate | 29 | $793 |
| Omeprazole | 28 | $612 |
| Prednisone | 73 | $523 |
| Gabapentin | 11 | $261 |
| Amlodipine Besylate | 41 | $195 |
| MethotrexateMethotrexate Sodium | 15 | $146 |
| Pantoprazole Sodium | 15 | $141 |
| Zolpidem Tartrate | 18 | $77 |
| Cilostazol | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Houston
- Philip WallerHouston$4.9M
- Qaiser RehmanHouston$2.3M
- Michelle EisenbergHouston$1.8M
- Abigail NeimanHouston$1.7M
- Wajeeha YousafHouston$1.3M
- Laila HassanHouston$870K
- Shervin AssassiHouston$667K
- Jacqueline VoHouston$520K
- Naureen AlimHouston$397K
- Paul PickrellAustin$40.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.